ARYx Therapeutics Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2005
2006
2007
2008
2009
Sales/Revenue
-
4,739.00
4,158.00
19,724.00
-
Cost of Goods Sold (COGS) incl. D&A
-
2,948.00
1,269.00
1,329.00
-
Gross Income
-
1,791.00
2,889.00
18,395.00
-
SG&A Expense
27,605.00
30,079.00
31,689.00
48,812.00
30,138.00
Interest Expense
671.00
1,324.00
1,352.00
1,928.00
2,007.00
Pretax Income
27,964.00
27,318.00
27,561.00
31,218.00
33,167.00
Consolidated Net Income
27,964.00
27,318.00
27,561.00
31,218.00
33,167.00
Net Income
27,964.00
27,318.00
27,561.00
31,218.00
33,167.00
Net Income After Extraordinaries
27,964.00
27,308.00
27,561.00
31,218.00
33,167.00
Net Income Available to Common
27,964.00
27,318.00
27,561.00
31,218.00
33,167.00
EPS (Basic)
30.73
26.84
8.24
1.65
1.21
Basic Shares Outstanding
910.00
1,018.00
3,346.00
18,964.00
27,438.00
EPS (Diluted)
30.73
26.85
8.24
1.65
1.21
Diluted Shares Outstanding
910.00
1,018.00
3,346.00
18,964.00
27,438.00
EBITDA
27,605.00
27,456.00
27,793.00
29,320.00
30,138.00
Non-Operating Interest Income
876.00
2,294.00
2,591.00
1,127.00
78.00
About ARYx Therapeutics
View Profile
